Therapy Areas: Central Nervous System
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
27 February 2026 - Gemma Biotherapeutics (GEMMABio), a US-based clinical-stage global genetic medicines company, announced on Thursday that it has dosed its first parent in the Phase 1/2 CHARISMA clin...
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
20 February 2026 - Biopharmaceutical company Lario Therapeutics announced on Thursday that it has received a total of USD2.4m in grant funding from The Michael J. Fox Foundation for Parkinson's R...
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
28 January 2026 - French medical imaging company Guerbet (Euronext Paris:GBT) announced on Tuesday that it has received approval from the European Commission for a new indication in children from birt...
Insilico Medicine signs co-development collaboration agreement with Hygtia Therapeutics
21 January 2026 - Insilico Medicine (HKEX: 3696), a Hong Kong-based clinical-stage biotechnology company that utilises generative artificial intelligence (AI), announced on Tuesday that it has signed ...
Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)
3 December 2025 - Rare disease pharmacy solutions provider Orsini announced on Tuesday that it has been chosen as a specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve), an FDA-appro...
Hemispherian secures US patent allowance expanding GLIX1 patent protection
19 November 2025 - Norwegian biotechnology company Hemispherian AS announced on Wednesday that the US Patent and Trademark Office has issued a Notice of Allowance for its patent application covering u...